Candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction: COMMENTARY

Majumdar, Sumit R.
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p60
Academic Journal
The article cites a medical study which states that candesartan reduced cardiovascular mortality and morbidity in chronic heart failure with low ejection fraction. The perils of overinterpreting subgroup analyses are well-known. The study by researchers combining CHARM-Added and CHARM-Alternative and examining only patients who had CHF with systolic dysfunction is better considered a prespecified individual patient data meta-analysis. It extends one's knowledge of how best to treat these high-risk patients. In patients who are relatively undertreated, adding the angiotensin II type 1-receptor blocker (ARB) candesartan led to important reductions in morbidity and mortality. These benefits accrued to all clinical and pharmacotherapy subgroups examined.


Related Articles

  • Extracorporeal membrane oxygenation after cardiac arrest in children: what do we know? Tajik, Myrthe; Cardarelli, Marcelo G. // European Journal of Cardio-Thoracic Surgery;Mar2008, Vol. 33 Issue 3, p409 

    Summary: The use of extracorporeal membrane oxygenation (ECMO) as a resuscitative measure during or after manual cardiopulmonary resuscitation (CPR) shows sharply contrasting results. To assess the added value of ECMO in this situation and looking for predictors of mortality we performed a...

  • Load-induced changes in repolarization: evidence from experimental and clinical data. Eckardt, Lars; Kirchhof, Paulus; Breithardt, Günter; Haverkamp, Wilhelm // Basic Research in Cardiology;Jul2001, Vol. 96 Issue 4, p369 

    The high incidence of arrhythmias in patients with heart failure, hypertension, valvular heart disease, or mitral walve prolapse suggests a strong link between wall motion abnormalities and arrhythmias. A potential common mechanism underlying these observations may be that overload leads to...

  • Highest-risk patients miss out on much-needed HF therapy.  // PharmacoEconomics & Outcomes News;9/24/2005, Issue 487, p11 

    Discusses research being done on the risk-treatment mismatch in the pharmacotherapy of heart failure. Reference to a study by D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy and A. Laupacis, published in the September 2005 issue of...

  • Cardiac risk and schizophrenia. Jindal, Ripu; MacKenzie, Erin M.; Baker, Glen B.; Yeragani, Vikram K. // Journal of Psychiatry & Neuroscience;Nov2005, Vol. 30 Issue 6, p393 

    Reports on the public health risk posed by sudden cardiac death after symptoms initially appear often without warning. Indication that patients with schizophrenia have been reported to be three times as likely to experience sudden unexpected death that individuals from the general population;...

  • A risk stratification tool predicted in-hospital mortality in acute decompensated heart failure. Granger, Christopher // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p57 

    This article presents information on a study related to risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree (CART) analysis was used to analyze 39 potential clinical variables of interest in the derivation cohort. Clinical...

  • Erythromycin and sudden cardiac death.  // Patient Care;Oct2004, Vol. 38 Issue 10, p10 

    Discusses research being done on the link between oral erythromycin and the risk of sudden death from cardiac causes. Reference to a study by W. A. Ray, K. T. Murray, S. Meredith et al, published in the 2004 issue of the "New England Journal of Medicine"; Mechanism at work to increase the risk.

  • Perindopril reduced cardiac events in stable coronary artery disease.  // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p31 

    The article focuses on the factors that help in reducing the cardiovascular events among patients with stable coronary artery disease. It examines if the angiotensin-converting enzyme (ACE) inhibitor perindopril reduce cardiac events in patients with stable coronary artery disease (CAD)....

  • Bias in the Evaluation of Effects of Statins on Mortality in Patients with Heart Failure. White, Jonathon; Stewart, Ralph // Heart, Lung & Circulation;Oct2014, Vol. 23 Issue 10, p989 

    No abstract available.

  • Evidence-based approach to exercise prescription in chronic heart failure. Selig, Steve E.; Hare, David L. // British Journal of Sports Medicine;Jul2007, Vol. 41 Issue 7, p407 

    The article discusses the implications of moderate exercise in chronic heart failure (CHF). It is inferred that cardiologists were concerned with recommending exercise to their patients with CHF because of the notion that habitual exercise training could accelerate the disease process through...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics